UBS Group
KAPA

UBS Group’s Kairos Pharma KAPA Stock Holding History

UBS Group’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Buy
+6,261
New +$3.25K ﹤0.01% 9350
2025
Q4 		– Sell
-5,979
Closed -$7K – 11370
2025
Q3 		$7K Sell
5,979
-3,479
-37% -$3.98K ﹤0.01% 8753
2025
Q2 		$6.71K Buy
9,458
+6,666
+239% +$4.85K ﹤0.01% 9067
2025
Q1 		$2.61K Sell
2,792
-8,053
-74% -$10.3K ﹤0.01% 9300
2024
Q4 		$16.5K Buy
+10,845
New +$16.6K ﹤0.01% 8001

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's KAPA Position: Q2 2026 in Review

UBS Group opened a new position in Kairos Pharma (KAPA) in Q2 2026: 6,261 shares worth $2.4K. The stake represents ﹤0.01% of the portfolio and ranks #9350 among its holdings. This is a return to the name: UBS Group previously reported a position in KAPA as recently as Q3 2025.

UBS Group first reported a position in KAPA in Q4 2024 and has held it in 5 quarters since. The position peaked at $16.5K in Q4 2024. 9 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • UBS Group held 6,261 shares of Kairos Pharma worth $2.4K as of Q2 2026.
  • Kairos Pharma was a new UBS Group position in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9350 holding.
  • UBS Group first reported a position in Kairos Pharma in Q4 2024 and has held it in 5 quarters since.
  • UBS Group's Kairos Pharma position peaked at $16.5K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.